Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...
Hosted on MSN

BMS bets on Janux’s novel solid tumour therapy through $850m deal

Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal will see the pair co-develop a novel therapy for the ...

Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story

Bristol-Myers Squibb (NYSE:BMY) reported positive top-line Phase 2 results for Reblozyl in alpha-thalassemia related anemia, ...
Hosted on MSN

JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
News-Press NOW

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal ...

Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation

Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2025 investor letter. A ...

Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty

Bristol-Myers Squibb stock remains a "Buy" given its high dividend, strong free cash flow yield, and valuation. Learn more ...